Trial · NCT03588936
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
NCT03588936, Phase 1, Terminated, Medical College of Wisconsin
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant. Trials, record NCT03588936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03588936
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
- NCT number
- NCT03588936
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 2 participants, actual
- Lead sponsor
- Medical College of Wisconsin
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- First posted
- 2018-07-17
- Last updated
- 2021-10-11
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum-tolerated Dose | Up to 4 weeks after last dose of study treatment (approximately 3 months) | Determine the safety and the maximum tolerated dose among two candidate doses of nivolumab in combination with tocilizumab for treatment of relapsed hematological malignancy post-allogeneic transplant. Maximum-tolerated dose is based on the determination of dose-limiting toxicities. |
| Secondary | Response Rates Based on Imaging | End of study treatment (approximately 2 months) | The number of subjects with stable disease as evidenced by imaging (Diagnostic positron emission tomography (PET)-CT scans or CT of the neck, chest, abdomen, and pelvis). |
| Secondary | Response Rates Based on Pathologic Response | End of study treatment (approximately 2 months) | The number of subjects with bone marrow response (achievement of complete response; \<5% blasts; stable disease; progressive disease). |
| Secondary | Overall Survival | Up to 1 year from beginning of treatment | The number of participants alive. |
| Secondary | Progression-Free Survival | Up to 1 year from beginning of treatment | Determine the number of subjects alive and in remission after treatment. |
| Secondary | Duration of response in responding participants | Up to 1 year from the beginning of treatment | Number of subjects with complete response or stable disease. |
| Secondary | Dose-limiting toxicities | Up to 4 weeks after last dose of study treatment (approximately 3 months) | The number of subjects with dose-limiting toxicities. This will be measured by the number of adverse events as defined by the NCI CTCAE version 4.03 non-hematologic ≥ grade 3-5 signs/symptoms or by the development of steroid refractory grade 2-4 graft-versus-host disease or severe chronic graft-versus-host disease. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03588936
GET https://conductscience.org/api/trials/v1/NCT03588936/registered